Renal amyloidosis pathophysiology

Jump to navigation Jump to search

Renal amyloidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Renal amyloidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiography or Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Template:Renal amyloidosis On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Renal amyloidosis pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Renal amyloidosis pathophysiology

CDC on Renal amyloidosis pathophysiology

Renal amyloidosis pathophysiology in the news

Blogs on Renal amyloidosis pathophysiology

Directions to Hospitals Treating Cystic fibrosis

Risk calculators and risk factors for Renal amyloidosis pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2]

Overview

The kidney is the most involved organ in systemic amyloiosis. Suggested mechanisms of renal involvement include abnormal protein production or hereditary mutation.

Pathophysiology

Pathogenesis

  • In systemic amyloidosis (AL/AH/AHL is much more common than AA) kidney is the most frequently involved organ.[1]
  • In renal amyloidosis, the mechanisms of amyloidogenesis may include:[2]
    • Abnormal protein production
    • Overproduction wild-type proteins
    • Decreased excretion of wild-type proteins
    • Hereditary mutation
  • In multiple myeloma, the cast nephropathy in distal tubules of nephrons results in renal impairment and deposition of AL amyloid protein in glomeruli can cause massive fibrillar involvement.[3]

Genetics

Hereditary amyloidosis due to amyloidogenic mutations:[4]

Associated Conditions

Gross Pathology

On gross pathology, amyloid looks "waxy" or "lardaceous" [7]

Microscopic Pathology

Microscopic Pathology of all types of amyloid after Congo red dye staining include: [2]

  • Orange-red appearance by normal light microscopy
  • Apple-green birefringence upon polarized light

For more general information about amyloidosis, click here.

References

  1. Said SM, Sethi S, Valeri AM, Leung N, Cornell LD, Fidler ME, Herrera Hernandez L, Vrana JA, Theis JD, Quint PS, Dogan A, Nasr SH (September 2013). "Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases". Clin J Am Soc Nephrol. 8 (9): 1515–23. doi:10.2215/CJN.10491012. PMC 3805078. PMID 23704299.
  2. 2.0 2.1 Khalighi MA, Dean Wallace W, Palma-Diaz MF (April 2014). "Amyloid nephropathy". Clin Kidney J. 7 (2): 97–106. doi:10.1093/ckj/sfu021. PMC 4377792. PMID 25852856.
  3. Hajra A, Bandyopadhyay D (2016). "An interesting case of renal amyloidosis". Indian J Nephrol. 26 (6): 467–469. doi:10.4103/0971-4065.177143. PMC 5131391. PMID 27942184.
  4. Mahmood S, Palladini G, Sanchorawala V, Wechalekar A (February 2014). "Update on treatment of light chain amyloidosis". Haematologica. 99 (2): 209–21. doi:10.3324/haematol.2013.087619. PMC 3912950. PMID 24497558.
  5. Ghiso J, Frangione B (December 2002). "Amyloidosis and Alzheimer's disease". Adv. Drug Deliv. Rev. 54 (12): 1539–51. PMID 12453671.
  6. Head E, Lott IT (April 2004). "Down syndrome and beta-amyloid deposition". Curr. Opin. Neurol. 17 (2): 95–100. PMID 15021233.
  7. Kyle RA (September 2001). "Amyloidosis: a convoluted story". Br. J. Haematol. 114 (3): 529–38. PMID 11552976.

Template:WH Template:WS